The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation.
Christopher ReillyAnandavelu RajaPillai AnilkumarJulie SullivanLisa WhiteAli BahronJulie MarshAdel Hasan MansurPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2023)
mepolizumab clinical benefit was sustained over 4 years. However, approximately half of the cohort discontinued the treatment prompting the need for further research into the treatment response longevity.